You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 10,463,676


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,463,676
Title:Modified-release dosage forms of 5-HT.sub.2C agonists useful for weight management
Abstract: The present invention relates to methods for weight management that utilize modified-release dosage forms comprising (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine salts and crystalline forms thereof. The present invention further relates to (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine salts, crystalline forms thereof and modified-release dosage forms comprising them.
Inventor(s): Shao; Zezhi Jesse (San Diego, CA), Blackburn; Anthony C. (San Diego, CA), Grottick; Andrew J. (Chula Vista, CA), Morgan; Michael E. (San Diego, CA), Rueter; Jaimie Karyn (San Diego, CA), Shifrina; Anna (Alameda, CA), Stirn; Scott (Rancho Santa Fe, CA), Yang; Libo (San Diego, CA), Yoon; Woo Hyun (San Diego, CA)
Assignee: Arena Pharmaceuticals, Inc. (San Diego, CA)
Application Number:16/241,337
Patent Claims: 1. A method of weight management in an individual in need thereof comprising administering once daily to said individual a modified-release dosage form which is a tablet, wherein the dosage form comprises a core tablet and a functional film coating, wherein said core tablet comprises: (i) about 7% by weight of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride salt hemihydrate, Form III, and (ii) about 50% by weight of (hydroxypropyl)methyl cellulose; wherein said functional film coating comprises ethyl cellulose and (hydroxypropyl)methyl cellulose in a weight ratio of about 85:15; and wherein said modified-release dosage form provides an in vitro release rate for which the time to achieve 80% release of said (R) 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (T80%) is at least 3 hours as determined by USP Apparatus I Basket Method in 900 mL of 0.1 N HCl solution at 37.degree. C. and 100 rpm.

2. The method of claim 1, wherein the weight to weight ratio of said core tablet to said functional coating is about 20:1.

3. The method of claim 1 or 2, wherein the core tablet further comprises microcrystalline cellulose.

4. The method of claim 3, wherein the core tablet comprises about 20% by weight of microcrystalline cellulose.

5. The method of claim 1 or 2, wherein the dosage form exhibits a release profile comprising super-case II kinetics under in vitro conditions.

6. The method of claim 1 or 2, wherein the core tablet further comprises mannitol.

7. The method of claim 1 or 2, wherein the core tablet further comprises magnesium stearate.

8. The method of claim 1, wherein said weight management comprises one or more of: weight loss, maintenance of weight loss, decreased food consumption, increasing meal-related satiety, reducing pre-meal hunger, and reducing intra-meal food intake.

9. The method of claim 1, as an adjunct to diet and exercise.

10. The method of claim 1, wherein said individual in need of weight management is selected from: an obese patient with an initial body mass index.gtoreq.30 kg/m.sup.2; an overweight patient with an initial body mass index.gtoreq.27 kg/m.sup.2 in the presence of at least one weight related comorbid condition; and an overweight patient with an initial body mass index.gtoreq.27 kg/m.sup.2 in the presence of at least one weight related comorbid condition; wherein said weight related co-morbid condition is selected from: hypertension, dyslipidemia, cardiovascular disease, glucose intolerance, and sleep apnea.

11. The method of claim 1, further comprising administering a second anti-obesity agent to said individual.

12. The method of claim 1, wherein said second anti-obesity agent is selected from: chlorphentermine, clortermine, phenpentermine, and phentermine, and pharmaceutically acceptable salts, solvates, and hydrates thereof.

13. The method of claim 1, further comprising administering an anti-diabetes agent to said individual.

14. The method of claim 1, wherein said anti-diabetes agent is metformin.

15. The method of claim 1, wherein the amount of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride salt hemihydrate, Form III is 20.8 mg per tablet.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.